Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]

Affiliations

• ¹ Istituto Europeo di Oncologia, Milan, IRCCS; University of Milano, Milan, Italy.
• ² Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany.
• ³ University of Colorado Hospital, Aurora.
• ⁴ Sarah Cannon Research Institute/Tennessee Oncology e Nashville, Nashville.
• ⁵ University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, USA.
• ⁶ Peter MacCallum Cancer Centre, Melbourne, Australia.
• ⁷ MD Anderson Cancer Center, Houston, USA.
• ⁸ The Royal Marsden NHS Foundation Trust, London, UK.
• ⁹ Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, USA.
• ¹⁰ Edinburgh Cancer Research Centre, Edinburgh, UK.
• ¹¹ UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.
• ¹² British Columbia Cancer e Vancouver Centre, Vancouver, Canada.
• ¹³ Dana-Farber Cancer Institute, Boston, USA.
• ¹⁴ German Breast Group, Neu-Isenburg, Germany.
• ¹⁵ Stanford Cancer Institute, Palo Alto, USA.
• ¹⁶ Seagen Inc., Bothell, USA.